Doximity Inc (DOCS)

Investment Committee Summary

Investment Thesis

Doximity operates a digital platform for medical professionals — a network business rather than a manufacturer, which is why it earns an operating margin near 47% on modest capital intensity and holds net cash of ~$0.2B. At $24.42 on 9 September 2026 the shares are fairly valued against the triangulated $22.34 (-9%), the probability-weighted target is $21.60, and the forward multiple sits near 17x. Two things should be said plainly. First, the engine routes the name through a life-science tools and services driver set — pharmaceutical customers' budgets and clinical funding — which captures roughly the right macro exposure but the wrong business model, so the archetype fit is loose. Second, the shares now sit far closer to the bottom of their 52-week range than the top, so a violent de-rating has already happened rather than being ahead. What decides the outcome is whether monetisation per active professional keeps rising when the customers funding it cut promotional budgets, because at this margin the operating leverage runs hard in both directions. The most damaging risk is a funding and spending reset among those customers, since there is no variable cost base to cut in response.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($24.42) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The bear mechanism is budget dependency. A platform earning an operating margin near 47% does so because serving one more professional costs close to nothing; the corollary is that its revenue is somebody else's discretionary spend. When development funding tightens or a launch calendar thins, promotional budgets are among the first lines cut, and the margin has no variable cost to shed in defence. A forward multiple near 17x on falling revenue then de-rates twice — earnings down, rating down — and the extraordinary width of the 52-week range is evidence that this market will reprice the name by a multiple of its value within a single year. The structural path lands below the 52-week low. One caution about the engine itself: its probability of the shares clearing today's price sits well under its own plausibility band, which points to a downside weighting more severe than the evidence supports.

Key Debate

P/E Multiple explains 90% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

What the Market Is Pricing In

At the current price, the market pays 18.1× consensus forward EPS, vs the house DCF terminal 13.0×, and a peer median 17.0×. The house DCF sits 2% below spot, so the market is pricing in more than the house case — roughly 0.2pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily growth-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Biopharma-Funding / China / Bioprocessing Reset' downside ($9.50) to a 'Bull — Re-Rate' bull case ($38.22); the probability-weighted blend (PWEV $21.60) is -12% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 20% of revenue; free cash flow net of SBC is $0.20B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Biopharma-Funding / China / Bioprocessing Reset (20%, $9.50). Structural impairment — biopharma-funding / China / demand reset: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• R&D-Spend Recession (17%, $16.14). Cyclical downturn — biopharma R&D & commercial budgets + consumable/service pull-through weakens for 1–2 years before normalising.
• Base — Tools + Services Growth (35%, $22.42). Mid-cycle — normalised biopharma R&D & commercial budgets + consumable/service pull-through; disciplined capital allocation; steady returns.
• Growth — Bioprocessing / Biologics Recovery (20%, $30.26). Upside — biopharma spend recovery + mix lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Re-Rate (8%, $38.22). Upside tail — sustained tight conditions or a structural re-rate on biopharma spend recovery + mix.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $19.57 and 25% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (90% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 13.0x terminal FCF multiple → $24.05. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $9.03; the peer-median forward P/E is 17.0x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 70% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Life-Science Tools, Services & Software multiple (AI re-rating) (base 15.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 17.3× (simple median 17.0×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $17.15–$76.51, centre $36.20 (+48% vs spot); spot sits at the 12th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Re-Rate): $38.22.

Company Overview & Business Model

Doximity Inc — HEALTHCARE · HEALTH INFORMATION SERVICES. Doximity, Inc. (Ticker: DOCS) is a U.S. healthcare technology company that operates a digital platform tailored for medical professionals. The company’s cloud-based network provides secure communication and collaboration tools, telemedicine services, clinical workflow solutions, and access to medical news, research, and career-management features for physicians, nurse practitioners, physician assistants, and other clinicians.

How it makes money.

Edge. Wide moat — inferred from a 47% operating margin and the Life-Science tools & services business model. Durable pricing power supports a terminal multiple above the market.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Care — Devices Tools

This name sits in the Health Care — Devices Tools cluster as a Life-Science tools, services & software name. biopharma R&D spend + bioprocessing/biologics demand + CRO/clinical funding. Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: ILMN (Life-Science tools, services & software) · MEDP (Life-Science tools, services & software) · PEN (medical devices & equipment) · GMED (medical devices & equipment) · BRKR (medical devices & equipment) · BIO (Life-Science tools, services & software) · AVTR (Life-Science tools, services & software) · LNTH (medical devices & equipment) · LIVN (medical devices & equipment) · NVST (medical devices & equipment) · DOCS (Life-Science tools, services & software) · HAE (medical devices & equipment) · XRAY (medical devices & equipment)

Mapping note: name-level 'Structural — Biopharma-Funding / China / Bioprocessing Reset' (20%) + 'R&D-Spend Recession' (17%) map to cluster Reimbursement / Funding / Utilization Reset (37%); name-level 'Growth — Bioprocessing / Biologics Recovery' (20%) + 'Bull — Re-Rate' (8%) map to cluster Upside — Innovation / Recovery Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Reimbursement / Funding / Utilization Reset — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The Health Care — Devices Tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex. Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Balance Sheet & Liquidity

Balance-sheet data as of 2026-03-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 166% — cash-backed.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q3): management +0.41 vs analyst floor +0.16 → delta +0.26 (n=20 mgmt / 14 Q&A; 20th pctile across the S&P book, z -0.9).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 124 articles): avg ticker sentiment -0.08 (bullish 8% / bearish 25%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Forecast Track Record

• EPS surprise: beat 75% of the last 8 quarters; average surprise +15.2%.
• Prior-forecast backtest (18 snapshots, 2026-07-21→2026-09-03): directional hit-rate 83%; mean predicted -8.2% vs realised +3.8%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

4 catalysts in the next 90 days (of 12 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 1 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic revenue growth / order backlog < flat-to-negative for two consecutive quarters (2 consecutive prints). Sustained demand rollover breaks the base case toward the recession scenario.
• FY revenue ($B) < 0.65 (next reported fiscal year). (rationale withheld pending re-authoring — frozen figure or verdict)
• Probability-weighted fair value (PWEV) at the next re-run < 24.42 (any scheduled re-run). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $24.42; 52-week range $17.15–$76.51; engine rating SELL; house target $21.60 (-12%). (source: Alpha Vantage 2026-09-08, 9 September 2026)
• INFERENCE: Triangulated FV $22.34 (-9% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits above the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

73.1/100 (confidence band 63.1–83.0), 96th percentile of 893 covered names (as of 2026-09-08). Weighted composite under config ros-1.20.0 — every component and its inputs below.

Score history: 71.9 → 71.7 → 71.7 → 71.9 → 71.7 → 71.2 → 72.5 → 72.3.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $21.6.

Factor Exposures

Cross-sectional percentiles over 893 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Portfolio Interaction (Focus Book)

This name is in the top-conviction focus book. Equal-weight book vol 10.4%; diversification benefit 70.3% vs the gross-weighted average single-name vol — combining correlation, the short leg hedging the long leg, and net exposure below 1.0; not diversification alone.

Options Intelligence

Preferred structure: Put Debit Spread. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• bearish with cheap options — buy defined-risk downside
• Direction bearish from the overlay conviction/rating (read-only input).
• IV/RV at the 2nd percentile of the cross-section → low vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 42nd percentile of its own month-end history (decile 5). The two measures disagree here — vol is high for this name by its own history while its options are not unusually rich against its realised vol. Where they diverge, the cross-sectional measure is the one acting.
• IV term structure is in contango (longer-dated richer, slope +29.2pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.
• No live-chain Put Debit Spread was priced for this name — shown as the indicated strategy; size against a freshly pulled chain.

IV term structure (contango, slope +29.2pp): 38-DTE 46% · 101-DTE 65% · 500-DTE 76%

No live-chain Put Debit Spread was priced for this name — shown as the indicated approach; size against a fresh chain.

Alternatives: Protective Put. IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

research rating is SELL-tier — the model carries no long position.

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the SELL equity view. Chain as of 2026-09-08 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 46.4% (subdued regime) · expected move ±12.1% (2026-10-16) · put/call OI 0.64 · ATM Δ 0.48 / Θ -0.02 / ν 0.03. Direction: NEUTRAL (implied return -8.5% to triangulated fair value $22.34).

Covered Call (if held) (Income / neutral) — Short 25 C · 2026-10-16 · premium $1.25 · yield 5.1% · priced from the listed chain (EOD marks)

Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Illustrative — no outcome is implied or guaranteed.

Put Spread (income) (Income / would-own) — Short 22.5 P / Long 20 P · 2026-10-16 · net $0.45 · net entry $22.05 · yield 2.0% · RoR 22.0% · max loss $2.05 · priced from the listed chain (EOD marks)

Gets paid to wait for a lower entry, with the tail capped: the sold put collects premium while the cheaper long wing below it caps the maximum loss at the spread width — a defined-risk alternative to a naked cash-secured put.

Protective Collar (if held) (Hedge) — Long 22.5 P / Short 27.5 C · 2027-02-19 · net $0.38 · floor -8.0% · cap +13.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -12% vs spot
• Monte Carlo median implies -20% vs spot
• DCF fair value implies -2% vs spot — but this is terminal-value sensitive (exit-multiple $24.05 vs Gordon $29.14, 21% apart), so it carries less weight
• Bear case (Structural — Biopharma-Funding / China / Bioprocessing Reset) downside is -61% vs spot
• Net: the valuation anchor itself sits 8.5% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $1B + PV(terminal) $3B = EV $4B; + net cash $0.2B → equity $4B ÷ diluted shares $0.18B = $24.05/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $29.14/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 38% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $9.03 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Terminal × ±15% (5.0); Revenue CAGR ±3pp (5.0); Op margin ±3pp (3.0); WACC ±1pp (2.0); Capex intensity ±15% (1.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 13×, FY+5 revenue $1B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.